Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer.

David Howard, David James,Jezabel Garcia-Parra,Belen Pan-Castillo,Jenny Worthington,Nicole Williams,Zoe Coombes, Sophie Colleen Rees,Kerryn Lutchman-Singh,Lewis W Francis,Paul Rees,Lavinia Margarit,R Steven Conlan,Deyarina Gonzalez

Frontiers in oncology（2022）

Cited 0|Views16

No score

Abstract

Dinaciclib proved highly efficacious in OC cell lines and primary cells, which were over a thousand-fold more sensitive to the CDKi than to cisplatin. Furthermore, cisplatin resistance in these cells did not influence sensitivity to dinaciclib and the two drugs combined additively in both platinum-sensitive and platinum-resistant OC cells suggesting a potential role for pan-CDKis (CDKis targeting multiple CDKs), such as dinaciclib, in the treatment of advanced and platinum-resistant OC.

Translated text

Key words

cisplatin,cyclin dependent kinase inhibitor,dinaciclib,flavopiridol,ovarian cancer,platinum,refractory,resistance

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined